All News

Meeting audience conference

ACR 2024 - Day 1 Report

Jack Cush, MD

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

Read Article
figure sitting in top of hourglass

axSpA: Moving the needle in time to diagnosis

Antoni Chan, MD, PhD

The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes. Data from the SPACE cohort (abstract 0566), the ASAS-PerSpA study (abstract 0550) and the US Claims data (abstract 0558), allows us to highlight the barriers to early diagnosis of axSpA and identify opportunities for improving early diagnosis and treatment.

Read Article
ACR Best

#ACR 2024 BEST Abstracts from Day 1

Jack Cush, MD

The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC.  Here are some of the best abstracts from Saturday Nov. 16th.

Read Article
GCA,woman

SELECT-GCA suggests JAKis may be the new kid on the block

Mrinalini Dey, MD

Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.

Read Article
pregnant, pregnancy, mother, fertility

Is Pregnancy Truly the Solution for RA?

Eric Dein, MD

Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or worsening of their autoimmune disease.

Read Article
The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it). https://t.co/GZ7tZ6fNMK Great for all US rheumatologists, but also very handy for all of us globally #ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR

Links:

David Liew drdavidliew ( View Tweet)
RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE

Links:

Dr. John Cush RheumNow ( View Tweet)

Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow

Richard Conway RichardPAConway ( View Tweet)

What is my risk of developing SLE? Abstract 0843 highlights a predictive model that accurately classifies SLE risk using genetics, lifestyle, and environmental factors. Model 3 (genetics + environment + lifestyle) performed the best compared to models 1 and 2. @RheumNow #ACR24 https://t.co/sk9oG0OY3W

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
Should we screen new #PMR pts for #LVV? Pts with PMR had lower risk of aortic complications vs #GCA & similar risk as gen pop BUT if they developed GCA later, the risk was same as those with new GCA ➡️Screening recommended in new GCA but not PMR pts Ab0859 #ACR24 @RheumNow https://t.co/HsHPGlt5A9

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
@abdelhamed012 @RheumNow Same https://t.co/uScez6UwBp

Links:

Richard Conway RichardPAConway ( View Tweet)
JAKs in PMR? "BACHELOR" study randomized 34pts to BARI vs PLBO Despite small sample, significant benefit at 12 wks (CRP PMR-AS < 10) for bari (78%) vs. PLBO (13%) Useful, but not for getting regulatory approval. Should have gone straight to phase 3! #ACR24 @RheumNow Abstr#0858 https://t.co/mmMs6c3AYC

Links:

Mike Putman EBRheum ( View Tweet)
How often should #scleroderma #ILD pts have #PFTs? 🤷‍♂️ Data from SENCIS RCT of SSc-ILD 25% worsened FVC by 6/12 Are we UNDER a ordering PFTs in an ILD #SSc population 👇 Because if worsening we would consider a change in background #immunesuppression @RheumNow #ACR24 #678 https://t.co/a9ybO3FwDd

Links:

Janet Pope Janetbirdope ( View Tweet)
Harkins @DrTrishHarkins et al. 1 year outcomes of 65 PMR patients treated in FTC. 32.7% experienced relapse, 28% still on GCs, 21% on tocilizumab. @RheumNow #ACR24 Abstr#0739 https://t.co/uYBYhPqGQE https://t.co/n9x9BDTPKg

Links:

Richard Conway RichardPAConway ( View Tweet)
Disparities posters #ACR24 - Analyzed 10,604 SLE patients - 18.7% in the lowest SES group experienced functional status decline vs. 12.5% in the highest SES group - African American patients and Greater neighborhood deprivation did worse #ACR24 abst#0190 @RheumNow

Bella Mehta bella_mehta ( View Tweet)

Contraception counselling in #SLE post intervention - Contraceptive counseling rates improved from 33.9% to 55.7% - Women over 35 were 4.09 times more likely post-intervention - Non-Hispanic Black women were less likely than Hispanic women #ACR24 abst#0184 @RheumNow https://t.co/sOZXnAe4ov

Links:

Bella Mehta bella_mehta ( View Tweet)
ASAS definition of Difficult-to-Manage Axial Spondyloarthritis (D2M axSpA) with criteria including treatment failure, suboptimal control, and persistent problematic symptoms. 89% of ASAS members endorsed the definition, including treatment-refractory cases with specific… https://t.co/3qWPQAGZ7c https://t.co/mVQzfLtaiI

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
The 2009 ASAS classification criteria did not meet the set targets of 75% sensitivity and 90% specificity in the CLASSIC cohort, indicating the need for revision of these criteria to increase its performance and validity in classification of axSpA. Abst#0820 #ACR24 #ACRBest… https://t.co/lF3QbRUpx3 https://t.co/SHPMpCjizS

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Researchers developed a digital messaging program to reduce fatigue in SLE - Grounded in social cognitive and self-determination theories - Reviewed 148 messages, refined based on patient feedback - High patient ratings, future will see more of these #ACR24 abst#0362 @RheumNow

Bella Mehta bella_mehta ( View Tweet)

Ab#0427 #ACR24 HSS: menopause & systemic rheum disease severity 1/3 women report worse disease associated w menopause Reported more flares, menopausal symptoms Findings were similar between SLE and RA, but SLE patients were >2x more likely to discuss w their rheum @RheumNow

Eric Dein ericdeinmd ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×